Drug Trial Radar · NCT00793624
Safety and Efficacy of BI 1744 CL in Patients With Chronic Obstructive Pulmonary Disease I
Last checked: Nov 19, 2026Latest source record: Jun 27, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
906
Actual
Start
Feb 2009
Primary completion
Dec 2010
Sponsor
- Lead sponsor
- Boehringer IngelheimBoehringer Ingelheim
- Sponsor type
- Industry
- First posted
- Nov 19, 2008
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double
- Primary purpose
- Treatment
- Who can join
- All sexes, from 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to assess the long-term efficacy and safety of once daily treatment of BI 1744 CL inhalation solution (5 and 10 mcg) delivered via the Respimat® inhaler, in patients with COPD.
Conditions
- Pulmonary Disease, Chronic Obstructive
Interventions
Olodaterol (BI 1744)Drug
Comparison of low and high doses on efficacy and safety in COPD patients
Olodaterol (BI 1744)Drug
Comparison of low and high doses on efficacy and safety in COPD patients
FormoterolDrug
Active comparator with Olodaterol (BI 1744) on safety and efficacy in COPD patients
PlaceboDrug
Placebo for comparison with Olodaterol (BI 1744) on safety and efficacy in COPD patients
PlaceboDrug
Placebo for comparison Formoterolon safety and efficacy in COPD patients
Primary outcomes
What the sponsor says the trial is designed to measure.
- Forced Expiratory Volume in One Second (FEV1) Area Under Curve 0-3 Hour (h) (AUC 0-3h) Response at 24 WeeksTime frame: 1 hour (h) and 10 minutes (min) prior to dose on the first day of randomized treatment (baseline) to -10 min, 5 min, 15 min, 30 min, 1 h, 2 h, and 3 h relative to dose on Week 24
- Trough FEV1 Response at Week 24Time frame: 1 h and 10 min prior to dose on the first day of randomized treatment (baseline) and -1 h (if available) and - 10 mins prior to study drug at week 24.
- Mahler Transitional Dyspnea Index Focal Score at 24 WeeksTime frame: Baseline, Week 24
- Mahler Transitional Dyspnea Index Focal Score at 24 Weeks for Combined AnalysisTime frame: Baseline, Week 24
Locations
93 sites in 20 countries. Site status is shown where the registry gives one.
1222.13.2401 Boehringer Ingelheim Investigational Site
Capital Federal, Argentina
1222.13.2403 Boehringer Ingelheim Investigational Site
Capital Federal, Argentina
1222.13.2402 Boehringer Ingelheim Investigational Site
Mar del Plata, Argentina
1222.13.2404 Boehringer Ingelheim Investigational Site
Monte Grande, Argentina
1222.13.2502 Boehringer Ingelheim Investigational Site
Juiz de Fora, Brazil
1222.13.2503 Boehringer Ingelheim Investigational Site
Rio de Janeiro, Brazil
1222.13.2505 Boehringer Ingelheim Investigational Site
Rio de Janeiro, Brazil
1222.13.2501 Boehringer Ingelheim Investigational Site
São Paulo, Brazil
1222.13.2504 Boehringer Ingelheim Investigational Site
São Paulo, Brazil
1222.13.1408 Boehringer Ingelheim Investigational Site
Calgary, Alberta, Canada
1222.13.1407 Boehringer Ingelheim Investigational Site
Chilliwack, British Columbia, Canada
1222.13.1403 Boehringer Ingelheim Investigational Site
Downsview, Ontario, Canada
1222.13.1412 Boehringer Ingelheim Investigational Site
Hamilton, Ontario, Canada
1222.13.1401 Boehringer Ingelheim Investigational Site
Niagara Falls, Ontario, Canada
1222.13.1410 Boehringer Ingelheim Investigational Site
Sarnia, Ontario, Canada
1222.13.1413 Boehringer Ingelheim Investigational Site
Toronto, Ontario, Canada
1222.13.1404 Boehringer Ingelheim Investigational Site
La Malbaie, Quebec, Canada
1222.13.1411 Boehringer Ingelheim Investigational Site
Montreal, Quebec, Canada
1222.13.1406 Boehringer Ingelheim Investigational Site
Point Claire, Quebec, Canada
1222.13.1402 Boehringer Ingelheim Investigational Site
Saskatoon, Saskatchewan, Canada
1222.13.3502 Boehringer Ingelheim Investigational Site
Dubrovnik, Croatia
1222.13.3503 Boehringer Ingelheim Investigational Site
Rijeka, Croatia
1222.13.3504 Boehringer Ingelheim Investigational Site
Split, Croatia
1222.13.3501 Boehringer Ingelheim Investigational Site
Zagreb, Croatia
1222.13.3401 Boehringer Ingelheim Investigational Site
Beroun, Czechia
1222.13.3403 Boehringer Ingelheim Investigational Site
Český Těšín, Czechia
1222.13.3402 Boehringer Ingelheim Investigational Site
Tábor, Czechia
1222.13.2003 Boehringer Ingelheim Investigational Site
Aalborg, Denmark
1222.13.2002 Boehringer Ingelheim Investigational Site
Hvidovre, Denmark
1222.13.2001 Boehringer Ingelheim Investigational Site
Silkeborg, Denmark
1222.13.2103 Boehringer Ingelheim Investigational Site
Lahti, Finland
1222.13.2101 Boehringer Ingelheim Investigational Site
Tampere, Finland
1222.13.2102 Boehringer Ingelheim Investigational Site
Turku, Finland
1222.13.1502 Boehringer Ingelheim Investigational Site
Berlin, Germany
1222.13.1503 Boehringer Ingelheim Investigational Site
Berlin, Germany
1222.13.1506 Boehringer Ingelheim Investigational Site
Berlin, Germany
1222.13.1501 Boehringer Ingelheim Investigational Site
Cologne, Germany
1222.13.1511 Boehringer Ingelheim Investigational Site
Dortmund, Germany
1222.13.1514 Boehringer Ingelheim Investigational Site
Essen, Germany
1222.13.1509 Boehringer Ingelheim Investigational Site
Großhansdorf, Germany
Showing 40 of 93 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.